Zhao Shuaixiang, Zhang He, Shang Guanning
The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.
Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
Front Immunol. 2025 May 30;16:1586759. doi: 10.3389/fimmu.2025.1586759. eCollection 2025.
B7 homolog 3 (B7-H3, also known as CD276) is a novel member of the B7 immune protein family. There is a marked difference in the expression and distribution of B7-H3 protein and mRNA between normal and tumor tissues, with widespread expression in tumor tissues and a close relationship with tumor progression. B7-H3 activates or inhibits tumor immune responses by binding to receptors on the surface of immune cells. Apart from participating in tumor immune activities, it has regulatory effects on non-immunological functions, such as tumor migration and invasion, angiogenesis, glycometabolism, and drug resistance. Thus, it has important biological functions in regulating the progression of malignant tumors. Current research on the structure, function, and therapeutic methods of B7-H3 is continuously breaking new ground, deepening our understanding of B7-H3, and promoting the development of therapeutic drugs targeting this new protein. This review briefly discusses the structure and distribution of B7-H3, as well as its immune and non-immune functions in the progression of cancer. It also summarizes the research progress on drugs targeting B7-H3 and the latest developments in clinical trials, highlighting their significant potential for the treatment of malignant tumors.
B7同系物3（B7-H3，也称为CD276）是B7免疫蛋白家族的一个新成员。正常组织与肿瘤组织之间，B7-H3蛋白和mRNA的表达及分布存在显著差异，其在肿瘤组织中广泛表达且与肿瘤进展密切相关。B7-H3通过与免疫细胞表面的受体结合来激活或抑制肿瘤免疫反应。除参与肿瘤免疫活动外，它对肿瘤迁移与侵袭、血管生成、糖代谢及耐药性等非免疫功能也具有调节作用。因此，它在调控恶性肿瘤进展中具有重要生物学功能。目前关于B7-H3的结构、功能及治疗方法的研究不断取得新进展，加深了我们对B7-H3的认识，并推动了针对这一新蛋白的治疗药物的开发。本文综述简要讨论了B7-H3的结构与分布，及其在癌症进展中的免疫和非免疫功能。还总结了靶向B7-H3的药物研究进展及临床试验的最新动态，突出了它们在治疗恶性肿瘤方面的巨大潜力。
